Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
23 hedge funds and large institutions have $11.8M invested in Astria Therapeutics in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 12 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
12% less funds holding
Funds holding: 26 → 23 (-3)
23.59% less ownership
Funds ownership: 62.58% → 38.99% (-24%)
72% less capital invested
Capital invested by funds: $42.1M → $11.8M (-$30.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$484K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$332K |
| 3 |
OC
Oppenheimer & Co
New York
|
+$207K |
| 4 |
Renaissance Technologies
New York
|
+$152K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.97M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$3.61M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.89M |
| 4 |
DM
Deerfield Management
New York
|
-$2.46M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.01M |
ATXS Hedge Fund Activity: Q1 2017 in Review
23 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2017, worth a combined $11.8M — down 72% from $42.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ATXS and 11 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Rhenman & Partners Asset Management, adding an estimated $484K. The largest seller was Fidelity Investments, exiting entirely with an estimated $4.97M sold.
- 23 institutional investors held Astria Therapeutics (ATXS) as of Q1 2017, down from 26 in Q4 2016.
- Funds reported $11.8M of Astria Therapeutics stock for Q1 2017, down 72% quarter-over-quarter.
- 11 funds opened new Astria Therapeutics positions in Q1 2017 and 12 closed out, a net change of -1 holder.
- The largest Astria Therapeutics buyer in Q1 2017 was Rhenman & Partners Asset Management, an estimated $484K added.
- The largest Astria Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $4.97M sold.
Based on aggregated 13F filings for Q1 2017.